Skip to main content

Table 3 Prognostic factors for survival

From: Efficacy of concurrent treatments in idiopathic pulmonary fibrosis patients with a rapid progression of respiratory failure: an analysis of a national administrative database in Japan

Variable

 

Univariate logistic analysis

Multivariate logistic analysis

N (%)

OR

95 % Cl

p-value

OR

95 % Cl

p-value

Age, years

209

      

 <60

17 (8.1)

ref

  

ref

  

 60–69

52 (24.9)

1.12

0.374–3.362

0.839

   

 70–79

98 (46.9)

1.83

0.647–5.196

0.254

   

 ≥80

42 (20.1)

3.78

1.110–12.858

0.033

2.94

1.044–8.303

0.041

Male

172 (82.3)

1.41

0.681–2.930

0.354

   

BMI, kg/m2

178

      

 <18.5

27 (15.2)

ref

     

 18.5–25

114 (64.0)

1.43

0.604–3.388

0.415

   

 >25

37 (20.8)

1.13

0.409–3.117

0.814

   

Brinkman Index

184

      

 0

68 (37.0)

ref

     

 1–800

45 (24.5)

1.37

0.617–3.046

0.439

   

 >800

71 (33.6)

1.14

0.571–2.271

0.712

   

F, H-J Classification scale

166

      

 1–4

41 (24.7)

ref

  

ref

  

 5

125 (75.3)

2.53

1.229–5.187

0.012

2.13

0.931–4.856

0.073

Specialty hospital care

173 (82.8)

0.83

0.382–1.799

0.635

   

Ambulance transfer

101 (48.3)

1.22

0.686–2.164

    

Performing bronchoscopy

20 (9.6)

0.19

0.068–0.506

0.001

0.25

0.079–0.798

0.019

Sivelestat

104 (49.8)

0.87

0.489–1.538

0.626

   

Diuretic drug

102 (48.8)

0.82

0.461–1.451

0.493

   

Anticoagulant therapy

87 (41.6)

0.52

0.292–0.933

0.028

   

Immunosuppressive therapy

75 (35.9)

0.66

0.366–1.193

0.17

   

Intravenous high-dose cyclophosphamide

32 (15.3)

1.38

0.601–3.160

0.449

3.17

1.101–9.148

0.033

PMX

13 (6.2)

1.17

0.347–3.935

0.801

   

Recombinant human soluble thrombomodulin

9 (4.3)

1.03

0.250–4.247

0.967

   

Antibiotic therapy

206 (98.6)

–

–

    

 β-Lactams

176 (84.2)

0.97

0.440–2.126

0.933

   

 Co-trimoxazole

115 (55.0)

0.20

0.103–0.388

<0.001

 

0.28

0.132–0.607

 Quinolones

103 (49.3)

0.77

0.436–1.372

0.38

   

 Macrolides

48 (23.0)

0.46

0.239–0.893

0.022

 

0.37

0.155–0.867

 Tetracycline

18 (8.6)

1.03

0.370–2.875

0.952

   

 Anti-MRSA antibiotics

17 (8.1)

0.94

0.332–2.651

0.904

   

 Clindamycin

5 (2.4)

0.33

0.054–2.042

0.235

   

 Aminoglycoside

3 (1.4)

0.25

0.022–2.826

0.264

   

 Others

12 (5.7)

0.71

0.216–2.307

0.564

   
  1. Data are presented as n (%), unless otherwise indicated. Definition of abbreviations: BMI body mass index, F, H-J Fletcher, Hugh-Jones, PMX Direct hemoperfusion with polymyxin B-immobilized fiber, MRSA Methicillin-resistant Staphylococcus aureus